This new histological subtype data confirms DecisionDx-Melanoma’s clinical value across the spectrum of melanoma
Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it is presenting data on its DecisionDx®-Melanoma test and its pipeline... Read more
Second SHORE Study Validates AlloSure Heart, an Integral Component of HeartCare, as a Reliable Biomarker for Antibody-Mediated Rejection in Heart Transplant Recipients SOUTH SAN FRANCISCO, Calif. / Oct 23, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced... Read more
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker... Read more
Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care... Read more
NEW YORK, Oct. 23, 2025 /PRNewswire/ -- BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead product BNT23001, a proprietary sublingual Cladribine formulation for the treatment of multiple sclerosis (MS). The study marks the final step before human bioequivalence testing, which is set to begin in early 2026.
A Final... Read more
Company Officially Launches Digital Asset Treasury Strategy Focused on the Highest Conviction Holdings of Arca Investment Management to Enhance Long-Term Shareholder Value ANN ARBOR, Mich. / Oct 23, 2025 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated... Read more
Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. Quarter three adjusted EBITDA was $396.7 million or 19.4% of revenue, representing an increase of 0.2% on quarter two 2025. Quarter three adjusted net income was $258.8 million or $3.31 per diluted ordinary share. Gross business wins in the quarter of $2,986 million, representing... Read more
Revenue of $659.9 million in the third quarter of 2025 increased 23.7% from revenue of $533.3 million for the comparable prior-year period, representing a backlog conversion rate of 23.0%.
Net new business awards were $789.6 million in the third quarter of 2025, representing an increase of 47.9% from net new business awards of $533.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.20x.
Third quarter of 2025 GAAP net income... Read more
PLAN CALCIUM study to be presented at TCT 2025 conference highlights how AI-powered plaque analysis can inform lesion preparation and calcium modification planning
NAVIGATE-PCI registry to enroll approximately 2,500 patients across approximately 30 sites to evaluate the impact of CT-guided PCI planning in real-world practice MOUNTAIN VIEW, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary... Read more
WILMINGTON, Mass. / Oct 22, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.
This agreement leverages an integrated approach to streamline discovery and characterization—bringing promising... Read more
Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive... Read more
WALTHAM, Mass. / Oct 22, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025.
Third Quarter Highlights Third quarter revenue grew 5% to $11.12 billion.
Third quarter GAAP diluted earnings per share (EPS) was $4.27, in-line with the prior-year quarter.
Third quarter adjusted EPS grew 10% to $5.79.
Delivered excellent operational performance... Read more
SOUTH SAN FRANCISCO, Calif. / Oct 22, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the appointment of Suresh Gunasekaran to its Board of Directors.
Suresh currently serves as President and Chief Executive Officer at UCSF Health, an internationally renowned health system... Read more
Third quarter revenues of $2.82 billion, up 13.1% from 2024
Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024
Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024
Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66; and adjusted diluted EPS is expected to be between $9.76 and $9.84 SECAUCUS, N.J., Oct. 21, 2025 /PRNewswire/... Read more
WASHINGTON, Oct. 21, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025.
Key Third Quarter 2025 Results Net earnings were $908 million, or $1.27 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.89.
Revenues increased 4.5% year-over-year to $6.1 billion and non-GAAP core revenue increased 3.0% year-over-year.
Operating cash flow was... Read more
VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, is pleased to announce the launch of an important large-mass animal bioequivalence study for its lead product, BNT23001, a proprietary sublingual Cladribine formulation for the treatment of multiple sclerosis ("MS"). This is the final animal study to generate... Read more
Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups highlighting the importance of proactive reanalysis offerings like Ambry’s Patient for Life™ program ALISO VIEJO, Calif. / Oct 20, 2025 / Business Wire / Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM),... Read more
Visit the CyPath® Lung team at Booth #2242 October 19-22 SAN ANTONIO / Oct 20, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced it will present research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The study supports the methods used to collect and transport patient samples for analysis by the... Read more
X-Chem’s DNA-encoded library complements Charles River’s discovery expertise to accelerate hit identification WILMINGTON, Mass. / Oct 20, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel... Read more
EL MONTE, Calif. / Oct 20, 2025 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in combination with cetuximab in ≤ 2nd line treatment of patients diagnosed... Read more
Data to be featured in Presidential Symposium at ESMO
Signatera™ changes the paradigm by expanding the adjuvant decision window, with up to 7 tests in the first year post-surgery, enabling effective initiation of treatment only after a positive test result, and allowing patients with persistently negative results to avoid unnecessary treatment AUSTIN, Texas / Oct 20, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision... Read more
Activity Report for Quarter Ended September 30, 2025 (Appendix 4C) NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2025.
Mesoblast Chief Executive Dr. Silviu Itescu said, “Revenues from sales of Ryoncil® continue to increase, driven by greater physician adoption... Read more
Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelines PALM SPRINGS, CALIFORNIA / ACCESS Newswire / October 17, 2025 / Desert Oasis Healthcare (DOHC) is proud to announce a partnership with RadNet, Inc. (locally known as Desert Advanced Imaging) to offer Enhanced Breast Cancer Detection (EBCD) and improve outcomes for women across the Coachella Valley. Effective immediately,... Read more
FDA-approved MTS™ DAT Card and advanced ORTHO VISION™ Platform highlight the company's continued leadership in transfusion medicine SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, will highlight its ongoing commitment to transfusion medicine excellence at the Association for the Advancement of Blood & Biotherapies (AABB) 2025 Annual Meeting. The company's participation coincides... Read more
New device has the potential to help empower decentralized PCR testing in nearly 30,000 primary health centers across India, advancing efforts to improve availability of life-saving TB diagnostics SALT LAKE CITY, Oct. 16, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the development of a proprietary... Read more
CHICAGO / Oct 16, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus’ proprietary... Read more
U.S. award protects AI-built platform and adds to growing international patent portfolio SAN ANTONIO, Texas / Oct 16, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced it has received a notification of allowance from the United States Patent and Trademark Office (USPTO)... Read more
WALTHAM, Mass. / Oct 16, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s proven growth strategy through the use of artificial intelligence (AI) with OpenAI. This collaboration will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost effectively.
Working with OpenAI, Thermo Fisher... Read more
15 abstracts spanning advancements in early detection of recurrence, tumor profiling, and therapy response monitoring
Presentations highlight the power of Guardant Health’s blood-based assays to reduce treatment burden and improve disease monitoring across multiple cancer types PALO ALTO, Calif. / Oct 15, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across its oncology portfolio... Read more
At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases
Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry, providing researchers with new tool for precision medicine breakthroughs SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the release of its novel 5-base solution,... Read more
CHICAGO / Oct 15, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany.
“We’re sharing research at ESMO Congress 2025, including two oral presentations, that highlight the growing role of real-world data and... Read more
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois.
Biodesix will be presenting data from an interim analysis of the CLARIFY study in a sponsored... Read more
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations SALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has added two genes, F8 and FXN, to the Foresight® Carrier Screen Universal Plus Panel.
“At Myriad Genetics, we carefully design the Foresight panel to... Read more
FORT MYERS, Fla. / Oct 14, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the presentation of assay-relevant data, including interventional therapy trials in progress, to showcase how its molecular residual disease (MRD) assay may benefit pharmaceutical partners at the European Society for Medical Oncology (ESMO) Congress 2025, October 17–21, in Berlin, Germany.... Read more
New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms designed to lower sequencing costs, add new multiomic capabilities, and expand support for regulated research environments.
The advancements center on new SPRQ-Nx... Read more
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its HiFi sequencing technology has been selected as the primary platform for the Korean Pangenome Reference Project, a landmark national initiative... Read more
Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1
Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2
Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3 MILFORD, Mass., Oct. 13, 2025... Read more
Company Also Intends to Appoint Jeff Dorman to Digital Asset Advisory Board ANN ARBOR, Mich. / Oct 13, 2025 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced an aggregate of $4.9 million in commitments for a... Read more
AUSTIN, Texas / Oct 13, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. 23, at 5:00 a.m. PT (8:00 a.m. ET) to discuss data in muscle-invasive bladder cancer that will be presented at the European Society for Medical Oncology (ESMO) Congress. This includes results from the randomized phase 3 IMvigor011 trial and from Checkmate 274.... Read more
Six oral presentations highlight Signatera’s expanding role across solid tumors, including definitive predictive data in adjuvant bladder cancer AUSTIN, Texas / Oct 12, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 17–21 in Berlin, Germany. The slate... Read more
Recognition highlights commercial potential of Telo's telomere-based MRD technology in the growing precision oncology market Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary multi-factor analysis of telomeres, today announced that the American Society of Hematology ("ASH") has... Read more
CHICAGO / Oct 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency’s ADAPT (Advanced Analysis for Precision Cancer Therapy) program.... Read more
VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, today announced that it has completed a Track One priority patent filing with the U.S. Patent and Trademark Office (USPTO) for its proprietary sublingual thin-film cladribine formulation (BNT23001), designed for the treatment of multiple sclerosis (MS).... Read more
HENDERSON, Nev., Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants. In addition, Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock and... Read more
SAN ANTONIO / Oct 09, 2025 / Business Wire / bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the previously announced definitive agreements for the purchase and sale of 720,000 shares of common stock at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq rules.
WallachBeth Capital,... Read more
Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio’s Revio system, powering one of the largest studies of healthy aging to date MENLO PARK, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that the National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate comprehensive genomic and epigenomic... Read more
Study Demonstrated a Sensitivity of 100% and Specificity of 95% Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasive blood-based screening test for the early detection of pancreatic cancer, initiated earlier this year. The study confirmed the strong clinical accuracy and... Read more
Launch Follows IM8’s Record Growth to $6.6 Million Monthly Revenue in September
IM8 Accelerates Toward $100 Million ARR Milestone with One of the Industry’s Fastest Growth Rates CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, today announced the launch of Daily Ultimate Longevity from its rapidly scaling IM8 Health brand co-founded by David Beckham. Daily Ultimate Longevity... Read more
WILMINGTON, Mass. / Oct 08, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Toxys today announced a collaboration that offers Charles River’s clients access to ReproTracker®, a state-of-the-art human stem cell-based in vitro assay that rapidly and reliably identifies developmental toxicity hazards of new drugs and chemicals.
As leveraged in the use of developmental and reproductive toxicology (DART) studies, ReproTracker complements... Read more
SAN ANTONIO / Oct 08, 2025 / Business Wire / bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing... Read more
